Melanoma News and Research

Latest Melanoma News and Research

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

DNA repair genes in melanoma tumours repair associated with poor response to chemotherapy: Research

A Link between the level of active DNA repair genes in melanoma tumours and the effectiveness of chemotherapy for skin cancer patients has been established for the first time by a team of scientists.The study, part-funded by Cancer Research UK and published in Clinical Cancer Research today (Friday), found that higher levels of DNA repair genes in melanoma tumours were associated with a poorer response to chemotherapy.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Genta Incorporated today announced financial results for the quarter ending June 30, 2010.

12 Aug 2010

Scientists develop new imaging technique to create three-dimensional images of melanoma

Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.

12 Aug 2010

Hybrid scanner helps to enhance visibility of skin cancer cells

Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.

12 Aug 2010

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Cascade Technologies, Inc., announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will receive NIH research funding through a collaboration with Omega Optical of Brattleboro, Vermont. This effort will accelerate development of a new class of medical endoscopes enhanced with proprietary multispectral imaging technology. The principal investigators on the project are Dr. Gary Carver, Director of Research at Omega Optical, and Dr. Daniel L. Farkas, Chairman and CEO of SMI.

11 Aug 2010

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Detection of malignant melanoma, the most serious type of skin cancer, will soon be quicker and easier thanks to the work of researchers at Missouri University of Science and Technology.The research, which is funded by the National Institutes of Health, recently received a patent titled "Automatic Detection of Critical Dermoscopy Features for Malignant Melanoma Diagnosis." The patent applies to a method for computer-aided analysis of photographs of skin lesions to detect the cancer. Melanoma can be cured if it is diagnosed early enough.

11 Aug 2010

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd - Cancer Research UK's commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

New laboratory to speed up research for melanoma treatment set up at University of Bristol

A new Skin Cancer Research Fund Laboratory has been set up in Bristol to study cancer cells collected from skin cancer patients attending Frenchay Hospital. It is hoped the new facility will speed up research into treatments for malignant melanoma - the most deadly form of skin cancer. The new laboratory at the Microvascular Research Laboratories at the University of Bristol will be officially opened today (Tuesday August 22nd) by the director of the Skin Cancer Research Fund, Mr Paul Townsend.

6 Aug 2010

Melanoma risk rises with the use of sunbeds: Study

According to an Australian Melanoma Family study, use of sunbeds to get a tan can increase the risk of developing melanoma by 41 per cent. The study looked into the effects of sunbeds on 18-39-year-olds and found that 23 per cent of participants who had melanoma reported using these machines.

5 Aug 2010

Scientists suggest home genetic tests may cause unnecessary stress

In the age of the Internet, where cybercondriacs are just a mouse click away from a diagnosis, do-it-yourself home genetics test may seem like the next logical step in managing health. But these tests, which are relatively new and available online, are often not comprehensive and may cause unnecessary stress, warns Suzanne Mahon, DNSc., a clinical professor of hematology and oncology at Saint Louis University.

5 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

Study solves puzzle behind different types of skin cancer on different body parts

A consistent all-over tan may be impossible to achieve because some body areas are much more resistant to tanning than others, a study has found.Researchers - funded by the Medical Research Council (MRC) - at the University of Edinburgh say the results explain why some holidaymakers find it so hard to achieve an even tan all over their body.

4 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

Melanoma News and Research

Latest Melanoma News and Research

New T cell engineering approach can improve success rate of immune-cell therapies

DNA repair genes in melanoma tumours repair associated with poor response to chemotherapy: Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Scientists develop new imaging technique to create three-dimensional images of melanoma

Hybrid scanner helps to enhance visibility of skin cancer cells

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Synta second-quarter net loss increases to $9.1 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

New research on use of medicine, diet to prevent UV-induced skin cancer

New laboratory to speed up research for melanoma treatment set up at University of Bristol

Melanoma risk rises with the use of sunbeds: Study

Scientists suggest home genetic tests may cause unnecessary stress

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Study solves puzzle behind different types of skin cancer on different body parts

ZymoGenetics second-quarter net loss declines to $3.8 million

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Melanoma News and Research

Latest Melanoma News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in